The Biologist Who Co‑Founded 23andMe
She co‑founded 23andMe. She left in 2009. She keeps building health startups.
Opening Scene
A young girl watches a sunrise over the prairie.
The sky glows pink.
She wonders how life works.
Childhood and Family
Linda was born Linda Bahnson in 1960.
Her home was in western South Dakota.
The land stretched far.
She grew up near open fields.
Public records do not list her parents or siblings.
She loved the natural world.
She asked why plants grow.
She spent long afternoons watching insects.
She collected rocks and leaves.
She felt a pull toward science.
She developed an early interest in the natural sciences during her upbringing in the region.
School Years
Linda went to August Academy University.
She studied biology.
She earned a B.A. in 1982.
College gave her lab skills.
She learned how DNA works.
She took courses in genetics.
She completed a senior project on cell metabolism.
She graduated with a Bachelor of Arts in biology.
First Jobs in Science
After college she joined UC Irvine.
She was a staff research associate.
She helped run experiments.
She worked in a molecular biology lab.
She learned techniques for DNA extraction.
She stayed at UC Irvine for several years.
Later she moved to sales.
She worked at Affymetrix.
She helped market microarray technology.
She also spent time at Perlegen Sciences.
She learned about large scale genotyping.
She added Spotfire to her resume.
She worked on data visualization tools.
She also worked at Applied Biosystems.
She sold laboratory instruments.
She built over 20 years of biotech sales experience.
She learned how to translate science into business.
The Idea Sparks
In the early 2000s DNA sequencing got cheaper.
Linda saw saliva could give DNA.
She imagined a kit you could use at home.
She wanted people to learn their own genetics.
She was inspired by the declining costs of DNA sequencing.
She realized that saliva was a viable, accessible DNA source.
She thought a consumer test could democratize genetic information.
She believed the data could accelerate medical research.
Founding 23andMe
In April 2006 Linda co‑founded 23andMe.
Her partners were Anne Wojcicki and Paul Cusenza.
Their goal: democratize genetic information.
They wanted to speed medical research.
Linda brought her biology background to the team.
She contributed scientific credibility.
She helped design the saliva collection method.
She worked on the early business model.
She helped secure early funding.
Early Growth of the Company
The first saliva test launched in 2007.
Customers mailed kits to labs.
Results came back in weeks.
High‑profile users included Jimmy Buffett and Yo‑Yo Ma.
The company built a database of early adopters.
The data helped refine risk reports.
The team added health reports in later versions.
The company raised capital from investors.
Google and Sergey Brin provided early funding.
The company grew its staff quickly.
It opened a lab in California.
It hired bioinformaticians to process data.
Challenges and Controversies
The founders faced privacy questions.
They needed informed consent forms.
Some feared life‑changing health news.
Regulators asked tough questions.
The FDA reviewed the health reports.
The company paused some health reports in 2013.
Ethical concerns about data use grew.
Anne Wojcicki later clashed with Linda over patents.
Linda left the board in 2009.
She cited fundamental disagreements regarding the patenting of genetic discoveries.
She described the exit as an ouster orchestrated to consolidate control.
Leaving 23andMe
Linda departed in 2009.
She said disagreements over patents drove her out.
She described the exit as an ouster.
She blamed poor governance later.
She said the company lost its way due to lack of consumer‑focused product development.
She remained publicly critical after the 2025 bankruptcy filing.
New Ventures and Investments
After 23andMe she helped start other health projects.
She co‑founded the Lifespan Project, a nonprofit focused on prevention and wellness.
She became a General Partner at Humain Ventures.
Humain invests in AI and biology startups.
She is a founding managing partner at Humain Ventures.
She advises Colossal Biosciences.
She advises NextSense.
She serves on the Board of Fellows at Stanford University School of Medicine.
She is a board director for the Human Immunome Project.
She co‑founded We Are Curious in 2011.
The platform helps people make sense of their health data.
She later became CEO of Precise.ly.
Precise.ly focuses on collecting genetic information from underserved communities.
Current Work in 2026
Linda now runs Humain Ventures from Austin.
She focuses on personalized medicine.
She pushes data from wearables and genomics.
She supports Alzheimer’s research, inspired by her late father‑in‑law.
She practices meditation and self‑reflection.
She believes mental health supports scientific work.
She continues to advise biotech companies.
She works with firms that blend AI and biology.
She speaks at industry conferences.
She mentors early founders.
Impact on the Industry
23andMe built a massive DNA database.
The company partnered with GSK in 2018.
It went public in 2021 with a $6 billion market cap.
It bought Lemonaid Health for $400 million.
The firm filed Chapter 11 in March 2025.
TTAM Research Institute bought it in July 2025.
Linda’s early work made consumer genetics possible.
Her vision showed that saliva could replace blood draws.
Her business model proved that direct‑to‑consumer testing could scale.
The data collected has been used in research studies.
The company’s approach changed how people think about personal health data.
Why the story matters
Linda shows how science can meet everyday life.
She proved a lab idea can become a household product.
Her path teaches founders to stay true to a problem.
Even after setbacks, she kept building.
The lesson: keep the mission alive.
DNA is a story we all can read.
The Record
Birth: 1960, western South Dakota
Education: B.A. Biology, Augustana University, 1982
First biotech role: UC Irvine, staff research associate, 1982
Co‑founder: 23andMe, 2006
Departure: 2009 (board)
Current role: Founding Managing Partner, Humain Ventures (2026)
Board service: Stanford School of Medicine, Human Immunome Project
Timeline
1960 to Born Linda Bahnson in western South Dakota.
1982 to Earned B.A. in biology from Augustana University.
1982 to Started at UC Irvine as research associate.
2006 to Co‑founded 23andMe with Anne Wojcicki and Paul Cusenza.
2007 to Launched first consumer DNA saliva test.
2009 to Left 23andMe board over patent disagreements.
2011 to Co‑founded Lifespan Project nonprofit.
2022 to Joined Humain Ventures as founding managing partner.
2025 to 23andMe filed Chapter 11; later acquired by TTAM Research Institute.
2026 to Active advisor to biotech and digital health firms.